Millennium Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Millennium Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.7M	Sell	722,121 -1,148,550	-61%	-$29.4M	0.01%	1268
2025 Q4	$46.8M	Buy	1,870,671 +968,403	+107%	+$24.5M	0.02%	867
2025 Q3	$21.9M	Sell	902,268 -755,619	-46%	-$13.4M	0.01%	1571
2025 Q2	$21.8M	Buy	1,657,887 +1,048,699	+172%	+$13.3M	0.01%	1496
2025 Q1	$8.76M	Buy	609,188 +210,737	+53%	+$3.45M	﹤0.01%	2322
2024 Q4	$6.67M	Buy	398,451 +168,072	+73%	+$2.78M	﹤0.01%	2559
2024 Q3	$3.68M	Buy	230,379 +180,894	+366%	+$2.22M	﹤0.01%	3115
2024 Q2	$447K	Sell	49,485 -237,908	-83%	-$2.26M	﹤0.01%	4659
2024 Q1	$3.25M	Buy	287,393 +244,906	+576%	+$2.32M	﹤0.01%	3294
2023 Q4	$338K	Buy	+42,487	New	+$285K	﹤0.01%	4904
2021 Q4	–	Sell	-337,002	Closed	-$5.63M	–	6868
2021 Q3	$5.63M	Sell	337,002 -211,450	-39%	-$4.38M	﹤0.01%	2734
2021 Q2	$12.2M	Buy	+548,452	New	+$12.9M	0.01%	1681

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management's CNTA Position: Q1 2026 in Review

Millennium Management reduced its Centessa Pharmaceuticals (CNTA) stake by 61% in Q1 2026, selling an estimated $29.4M and leaving 722,121 shares worth $28.7M. The position accounts for 0.01% of the portfolio, ranked #1268.

Millennium Management first reported a position in CNTA in Q2 2021 and has held it in 12 quarters since. The position peaked at $46.8M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Millennium Management held 722,121 shares of Centessa Pharmaceuticals worth $28.7M as of Q1 2026.
Millennium Management sold 1,148,550 Centessa Pharmaceuticals shares in Q1 2026, an estimated $29.4M.
Centessa Pharmaceuticals made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1268 holding.
Millennium Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
Millennium Management's Centessa Pharmaceuticals position peaked at $46.8M in Q4 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.